Thrombotic and embolic complications with silastic ball prosthetic valves

Q. Macmanus, M. T. Metzdorff, G. L. Grunkemeier, Albert Starr

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8% per year and 2.8% per year for the aortic valve; and 5.1% per year and 2.6% per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1% per patient year and 0.4% per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.

Original languageEnglish (US)
Pages (from-to)59-63
Number of pages5
JournalEuropean Heart Journal
Volume5
Issue numberSUPPL. D
StatePublished - 1984

Fingerprint

Prostheses and Implants
Aortic Valve
Mitral Valve
Pathologic Constriction
Thrombosis
baysilon
Databases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Macmanus, Q., Metzdorff, M. T., Grunkemeier, G. L., & Starr, A. (1984). Thrombotic and embolic complications with silastic ball prosthetic valves. European Heart Journal, 5(SUPPL. D), 59-63.

Thrombotic and embolic complications with silastic ball prosthetic valves. / Macmanus, Q.; Metzdorff, M. T.; Grunkemeier, G. L.; Starr, Albert.

In: European Heart Journal, Vol. 5, No. SUPPL. D, 1984, p. 59-63.

Research output: Contribution to journalArticle

Macmanus, Q, Metzdorff, MT, Grunkemeier, GL & Starr, A 1984, 'Thrombotic and embolic complications with silastic ball prosthetic valves', European Heart Journal, vol. 5, no. SUPPL. D, pp. 59-63.
Macmanus Q, Metzdorff MT, Grunkemeier GL, Starr A. Thrombotic and embolic complications with silastic ball prosthetic valves. European Heart Journal. 1984;5(SUPPL. D):59-63.
Macmanus, Q. ; Metzdorff, M. T. ; Grunkemeier, G. L. ; Starr, Albert. / Thrombotic and embolic complications with silastic ball prosthetic valves. In: European Heart Journal. 1984 ; Vol. 5, No. SUPPL. D. pp. 59-63.
@article{0e3b9a02cd68432f89ab31d3994c407f,
title = "Thrombotic and embolic complications with silastic ball prosthetic valves",
abstract = "Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8{\%} per year and 2.8{\%} per year for the aortic valve; and 5.1{\%} per year and 2.6{\%} per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1{\%} per patient year and 0.4{\%} per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.",
author = "Q. Macmanus and Metzdorff, {M. T.} and Grunkemeier, {G. L.} and Albert Starr",
year = "1984",
language = "English (US)",
volume = "5",
pages = "59--63",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. D",

}

TY - JOUR

T1 - Thrombotic and embolic complications with silastic ball prosthetic valves

AU - Macmanus, Q.

AU - Metzdorff, M. T.

AU - Grunkemeier, G. L.

AU - Starr, Albert

PY - 1984

Y1 - 1984

N2 - Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8% per year and 2.8% per year for the aortic valve; and 5.1% per year and 2.6% per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1% per patient year and 0.4% per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.

AB - Eighteen years of continous clinical use with the Starr-Edwards ball-valve prosthesis provides an extensive data base for comparison with more recently introduced cardiac prostheses, and establishes the credentials of this valve for current clinical use. Since 1965, 558 aortic (model 1260) and 285 mitral (model 6120) ball-valve prostheses have been inserted at the University of Oregon. Thromboembolic rates for the entire series (1965-1983) and our more recent experience (1973-1983) were 3.8% per year and 2.8% per year for the aortic valve; and 5.1% per year and 2.6% per year for the mitral valve. Patients who had experienced one embolic episode were substantially more likely to experience a subsequent event. Thrombotic stenosis was seen at rates of 0.1% per patient year and 0.4% per patient year for the aortic and mitral valves, respectively. These results are compared with other current series using a variety of mechanical and tissue protheses. The Starr-Edwards valve remains a durable mechanical cardiac prosthesis with thromboembolic complications similar to most other current prostheses. Thrombotic stenosis tends to be rare, gradual, and electively managed as opposed to the sudden, unpredictable, and catastrophic thrombosis seen with tilting disc valves.

UR - http://www.scopus.com/inward/record.url?scp=0021717366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021717366&partnerID=8YFLogxK

M3 - Article

C2 - 6519104

AN - SCOPUS:0021717366

VL - 5

SP - 59

EP - 63

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. D

ER -